EA200701687A1 - Гидрохлорид аморфного лерканидипина - Google Patents

Гидрохлорид аморфного лерканидипина

Info

Publication number
EA200701687A1
EA200701687A1 EA200701687A EA200701687A EA200701687A1 EA 200701687 A1 EA200701687 A1 EA 200701687A1 EA 200701687 A EA200701687 A EA 200701687A EA 200701687 A EA200701687 A EA 200701687A EA 200701687 A1 EA200701687 A1 EA 200701687A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lorkanidipine
substantially pure
amorphous hydrochloride
pure amorphous
amorphous lercanidipine
Prior art date
Application number
EA200701687A
Other languages
English (en)
Other versions
EA014383B1 (ru
Inventor
Амедео Леонарди
Гьянни Мотта
Фабио Берлати
Original Assignee
Рекордати Айерленд Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36585434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200701687(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Рекордати Айерленд Лимитед filed Critical Рекордати Айерленд Лимитед
Publication of EA200701687A1 publication Critical patent/EA200701687A1/ru
Publication of EA014383B1 publication Critical patent/EA014383B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C07B63/04—Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

Изобретение предусматривает получение в основном чистого гидрохлорида аморфного лерканидипина, имеющего степень чистоты по меньшей мере 95%, предпочтительно приблизительно по меньшей мере 97%, более предпочтительно по меньшей мере приблизительно 99% и еще более предпочтительно по меньшей мере приблизительно 99,5%. Изобретение дополнительно предусматривает создание способов получения в основном чистого аморфного лерканидипина и фармацевтических композиций, содержащих в основном чистый аморфный лерканидипин.
EA200701687A 2005-02-25 2006-02-24 Гидрохлорид аморфного лерканидипина EA014383B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65683605P 2005-02-25 2005-02-25
PCT/EP2006/001782 WO2006089787A1 (en) 2005-02-25 2006-02-24 Amorphous lercanidipine hydrochloride

Publications (2)

Publication Number Publication Date
EA200701687A1 true EA200701687A1 (ru) 2008-02-28
EA014383B1 EA014383B1 (ru) 2010-10-29

Family

ID=36585434

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701687A EA014383B1 (ru) 2005-02-25 2006-02-24 Гидрохлорид аморфного лерканидипина

Country Status (32)

Country Link
US (1) US7820701B2 (ru)
EP (1) EP1856051B1 (ru)
JP (1) JP2008531515A (ru)
KR (1) KR20070105979A (ru)
CN (1) CN101124204A (ru)
AR (1) AR052918A1 (ru)
AU (1) AU2006218026B9 (ru)
BR (1) BRPI0608138A2 (ru)
CA (1) CA2598016A1 (ru)
CY (1) CY1122429T1 (ru)
DK (1) DK1856051T3 (ru)
EA (1) EA014383B1 (ru)
ES (1) ES2339213T3 (ru)
HR (1) HRP20192302T1 (ru)
HU (1) HUE046910T2 (ru)
IL (1) IL184349A0 (ru)
LT (1) LT1856051T (ru)
ME (1) ME03659B (ru)
MX (1) MX2007010093A (ru)
MY (1) MY142129A (ru)
NO (1) NO344559B1 (ru)
NZ (1) NZ556667A (ru)
PE (1) PE20061014A1 (ru)
PL (1) PL1856051T3 (ru)
PT (1) PT1856051T (ru)
RS (1) RS59654B1 (ru)
SI (1) SI1856051T1 (ru)
TW (1) TW200640861A (ru)
UA (1) UA90130C2 (ru)
UY (1) UY29401A1 (ru)
WO (1) WO2006089787A1 (ru)
ZA (1) ZA200708127B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4709545B2 (ja) * 2002-07-26 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 修飾された低分子干渉ｒｎａ分子および使用方法
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
US8097729B2 (en) 2005-09-16 2012-01-17 Glenmark Generics Ltd. Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
SI2046745T1 (sl) * 2006-08-04 2014-02-28 Recordati Ireland Limited Postopek za pripravo amorfnega lerkanidipin hidroklorida
EP2101771A2 (en) * 2006-12-06 2009-09-23 Torrent Pharmaceuticals Ltd Stable lercanidipine formulation
EP2121575A2 (en) * 2007-03-05 2009-11-25 Actavis Group PTC EHF Lercanidipine hydrochloride polymorphs and an improved process for preparation of 1,1,n-trimethyl-n-(3,3-diphenylpropyl)-2-aminoethyl acetoacetate
CA2761255C (en) * 2009-05-12 2017-05-09 Corcept Therapeutics, Inc. Solid forms and process for preparing (r)-4a-ethoxymethyl-1-(4-fluoro-phenyl)-6-(4-trifluoromethyl-benzenesulfonyl)-4,4a,5,6,7,8-hexahydro-1h,1,2,6-triaza-cyclopenta[b]naphthalene
DE102010005124A1 (de) * 2010-01-19 2012-03-01 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung umfassend Lercanidipin
EP2444394A1 (en) 2010-10-21 2012-04-25 Alembic Pharmaceuticals Limited Process for the preparation of amorphous form of lercanidipine HCI
CN102531999B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 无定形盐酸乐卡地平及其制备方法
CN102558032B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 一种无定形盐酸乐卡地平及其制备方法
CN102600146B (zh) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
WO2015029066A1 (en) * 2013-08-29 2015-03-05 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US5696139A (en) * 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
US5912351A (en) * 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof
IT1274480B (it) 1995-05-12 1997-07-17 Recordati Chem Pharm Procedimento migliorato per la preparazione della lercanidipina cloridrato
US20030069285A1 (en) * 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
ITMI20011727A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Solvati della lercanidipina cloridrato e nuove forme cristalline della lercanidipina cloridrato ottenute da essi
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US20030180355A1 (en) * 2001-10-16 2003-09-25 Amedeo Leonardi Combination therapy for hypertension
US20040147566A1 (en) * 2002-10-16 2004-07-29 Amedeo Leonardi Lisinopril/lercanidipine combination therapy
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
TW200613275A (en) * 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
TW200616681A (en) 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
KR100651212B1 (ko) 2004-10-27 2006-12-01 제일약품주식회사 무정형 레르카니디핀의 제조방법
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
US8097729B2 (en) 2005-09-16 2012-01-17 Glenmark Generics Ltd. Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
EP1963254A2 (en) 2005-09-21 2008-09-03 Torrent Pharmaceuticals Ltd Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride
SI2046745T1 (sl) 2006-08-04 2014-02-28 Recordati Ireland Limited Postopek za pripravo amorfnega lerkanidipin hidroklorida

Also Published As

Publication number Publication date
EP1856051A1 (en) 2007-11-21
DK1856051T3 (da) 2020-01-02
IL184349A0 (en) 2007-10-31
CN101124204A (zh) 2008-02-13
EA014383B1 (ru) 2010-10-29
NO344559B1 (no) 2020-02-03
JP2008531515A (ja) 2008-08-14
AU2006218026B9 (en) 2011-10-27
MY142129A (en) 2010-09-30
PL1856051T3 (pl) 2020-05-18
CA2598016A1 (en) 2006-08-31
US20060211742A1 (en) 2006-09-21
BRPI0608138A2 (pt) 2009-11-17
US7820701B2 (en) 2010-10-26
CY1122429T1 (el) 2021-01-27
PE20061014A1 (es) 2006-10-03
UY29401A1 (es) 2006-06-30
AU2006218026B2 (en) 2009-04-02
ES2339213T3 (es) 2020-05-28
PT1856051T (pt) 2020-01-07
NO20074874L (no) 2007-11-26
ES2339213T1 (es) 2010-05-18
LT1856051T (lt) 2020-01-10
TW200640861A (en) 2006-12-01
WO2006089787A1 (en) 2006-08-31
RS59654B1 (sr) 2020-01-31
UA90130C2 (ru) 2010-04-12
KR20070105979A (ko) 2007-10-31
HUE046910T2 (hu) 2020-04-28
NZ556667A (en) 2009-10-30
MX2007010093A (es) 2007-10-12
AR052918A1 (es) 2007-04-11
SI1856051T1 (sl) 2020-02-28
HRP20192302T1 (hr) 2020-03-06
ME03659B (me) 2021-01-20
AU2006218026A1 (en) 2006-08-31
ZA200708127B (en) 2008-11-26
EP1856051B1 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
EA200701687A1 (ru) Гидрохлорид аморфного лерканидипина
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
CY1117228T1 (el) Διεργασια για την παρασκευη συνθεσεων υδροχλωρικης οξυκωδονης που εχουν λιγοτερο απο 25 ppm 14-υδροξυκωδεϊνονη
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
ATE465719T1 (de) Oral zerfallende zusammensetzung von olanzapin oder donepezil
EP1416933B8 (en) Substituted piperidines as modulators of the melanocortin receptor
CY1117051T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν κρυσταλλικη μορφη (i) της υδροχλωριουχου λερκανιδιπινης
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
NO20043367L (no) Oralt farmasoytisk preparat
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
DK3219705T3 (da) Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
WO2008064353A3 (en) 7,8-saturated-4,5-epoxy-morphinanium analogs
EA200600323A1 (ru) γd-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
MX2008002061A (es) Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
EA200700673A1 (ru) Твердая фармацевтическая композиция, содержащая донепезила гидрохлорид
RS98704A (en) New pharmaceutical compositions containing flibanserin polymorpha
MXPA05013758A (es) Composiciones farmaceuticas que incluyen una antihistamina y un estimulante y uso de las mismas.
BRPI0610156A2 (pt) forma micronizada de um composto, forma purificada i do composto, kit, padrão de referência, e, método de preparaçao de uma composição farmacêutica.
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
EA200701686A1 (ru) Свободное основание лерканидипина
WO2006004903A3 (en) 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
WO2007069050A3 (en) Processes for the preparation of alfuzosin
MX2008002073A (es) Compuestos para el tratamiento de trastornos inflamatorios.
HUP0401895A2 (hu) Paroxetin N-formil származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP1406614A4 (en) CARVEDILOLPOLYMORPH